ALK and non-small cell lung carcinoma: A second reason for the relatively long OS might be repeat implementation of local therapies for oligoprogression (Fig. 1B,E), which confer additional survival benefit, as documented for both ALK+ and wild-type NSCLC (Weickhardt et al. 2012; Rheinheimer et al. 2020).